Hepatitis C

3rd EU HCV Elimination Policy Summit
May 2020

Securing Wider EU Commitment to the Elimination of HCV

3rd EU HCV Elimination Policy Summit May 2020

"Securing Wider EU Commitment to the Elimination of HCV"

Please find below the link to the Press release 
“An Interview of Professor Angelos Hatzakis, Co-chair of Hepatitis B and C Public Policy Association on the EU strategy and potential financial tools to eliminate HCV infection”.



Address to the 2nd EU HCV Summit “Securing sustainable funding for Hepatitis C Virus elimination plans”
George Papandreou,
President of Socialist International and former prime minister of Greece.

pdfDownload document

EU Hepatitis C Policy Summit

Securing sustainable funding for Hepatitis C Virus
elimination plans

Hepatitis C is a major public health problem in Europe with significant morbidity and mortality rates. In the EU more people die each year from HCV than from HIV. An estimated 15 million Europeans are chronically infected, including 5.5 million living in the EU. Even with Europe’s generally good tracking of epidemics, HCV continues to spread undetected as a “silent pandemic” as patients often have no symptoms during the first 20-30 years. In addition to the suffering of patients, the economic burden of the disease is significant due to healthcare costs and indirect loss of productivity In Europe is considerable.

Read more

Policy Guidelines

Hepatitis C Elimination in Europe
European Policy Guidelines

pdfHCV Elimination PolicyGuidelines

HepBandC logo

About us

In April 2009, a group of leading European scientists, public health experts and patient advocates created the Hepatitis B and C Summit Conferences Association as a Luxembourg-based not-for-profit Association.

The aim of the association is to urge and facilitate the formulation of public policies at national and international level for the communication, prevention and management of the spread of viral Hepatitis B and C. The Association’s unique approach in furtherance of this aim is to gather together, and work in partnership with, the major stakeholders in the field of these diseases including regulators, patients, clinicians, public health and civil society communities and the private sector.

Read more

With financial support of

Official endorsements